US FDA approves Bristol Myers Squibb's CAR T-cell therapy, Breyanzi, for relapsed/refractory follicular lymphoma.
The US FDA has approved Bristol Myers Squibb's CAR T-cell therapy, Breyanzi (lisocabtagene maraleucel), for treating adults with relapsed or refractory follicular lymphoma who have previously been treated with two or more lines of therapy. The approval is based on data from the TRANSCEND-FL trial, which demonstrated an overall response rate of 95.7%.
May 15, 2024
9 Articles